Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Overweight rating and $11 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Eupraxia Pharmaceuticals to Present at Key Investor Conferences
- Promising Developments in Eupraxia Pharmaceuticals’ EoE Trial Justify Buy Rating
- Eupraxia Pharmaceuticals Advances RESOLVE Trial with First Patient Dosed in Phase 2b
- Eupraxia Pharma doses first patient in Phase 2b trial of EP-104GI in esophagitis
- Promising Future for Eupraxia Pharmaceuticals: Buy Rating Affirmed on Strong EP-104GI Trial Results